BOSTON, Oct. 3, 2016 /PRNewswire/ -- ZappRx (zapprx.com), a digital specialty prescribing platform focused on increasingpatient access to therapy, today announced the appointment of Peter Wirth as Executive Chairman.
"Peter's outstanding reputation as a thought leader and corporate deal maker in the biotechnology industry makes him
Wirth brings more than 40 years of biotechnology expertise to ZappRx. He is currently Chairman of the Board of FORMA Therapeutics Holdings, LLC, a cancer drug discovery company. Prior to that, Wirth served Genzyme Corporation as Secretary to the Board of Directors and outside general counsel from 1982 until its acquisition by Sanofi. From January 1996 through May 2011, Wirth was a senior executive at Genzyme, most recently serving as Executive Vice President, Legal and Corporate Development, Chief Risk Officer, and Corporate Secretary.
Wirth worked closely with Henri Termeer, Genzyme's CEO, to build the company from a small start-up to a diversified enterprise with more than 12,000 employees in locations spanning the globe and 2009 revenues of $4.5 billion. Genzyme was named a Fortune 500 company in 2010 and was acquired by Sanofi-Aventis in a transaction valued at more than $20 billion in April 2011.
"The specialty prescription ordering process isn't working as well as it should for key stakeholders," said Wirth. "I am honored to join ZappRx and work closely with their innovative Board of Directors and executive team to improve patient access to therapy and bring clinical data insights directly to the pharmaceutical industry."
U.S. spending on prescription drugs in 2015 reached $457B. By the year 2020, spending on specialty drugs alone is projected to reach $400B. Although representing less than 2% of prescriptions written, specialty drugs account for almost 40% of overall prescription drug spending. However, the process of getting a drug from prescription to patient is cumbersome, fragmented, and results in a critical lack of rich clinical and timely data to improve the patient access.
ZappRx is modernizing and simplifying the way specialty medications are managed. The company provides a secure, collaborative online platform that allows patients, physicians and pharmacists to work together to improve patients' access to treatment, delivering medicine faster, with fewer hassles and greater transparency. ZappRx is on the web at ZappRx.com. Follow ZappRx on Twitter at twitter.com/zapprx.
Heath Umbach, Sr. Director of Marketing and Business Development
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/zapprx-appoints-peter-wirth-executive-chairman-300337196.html
Subscribe to our Free Newsletters!
Fallot's tetralogy is a rare and complex birth defect of the heart. Babies born with this condition ...
Bubonic plague is an infectious disease caused by the bacteria Yersinia pestis present in rodents ...
Steroids are miracle drugs but have to be used with caution. Some steroids are illegal to use, ...View All